Back to Authors

Wang, Lingxiang

Mayo Clinic

Mayo Clinic

Citations 2

A novel mouse model of diverse tumors derived from epithelial cells
Wang, Lingxiang, Liu, Yang, Jahan‐mihan, Yasmin , He, Gordon, Hu, Jie , Bi, Yan , Ji, Baoan , Jahan-mihan, Yasmin, Wang, Yuxi, Ji, Baoan , Wang, Bin , Liu, Yang, He, Gordon, Wang, Di , Wang, Jiale

Physiological Reports | March 30, 2025 | Volume: 13 | Issue: 7 | Pages: No page available

10.14814/phy2.70289 Get It

AbstractA deeper understanding of pathophysiology, from the initiation of tumors of epithelial cells to the outcomes associated with it, is imperative to test potential interventions for these diseases. However, few models can accomplish this because of the complexity of origin cells and their transformation. We established an epithelial cell original tumor mouse model by conditional KrasG12D activation and tumor suppressor gene p53 deletion specifically in epithelial cells of the whole body using Cytokeratin 19 (CK19) promoter via Cre‐ERT mediation. Multiple tumors derived from epithelial cells developed in this novel model. This model can recapitulate the progress of intestinal, pancreatic, liver, lung, and subcutaneous tumors which derive from epithelial cells. This model is suitable for studying the pathophysiology of tumors derived from epithelial cells and may have the potential to test interventions.
A simple and effective genotyping workflow for rapid detection of CRISPR genome editing
Wang, Lingxiang, Wang, Jiale , Feng, Dongfeng , Jahan‐mihan, Yasmin , Bi, Yan , Lim, DoYoung, Ji, Baoan , Jahan-mihan, Yasmin, Bi, Yan , Ji, Baoan , Wang, Jiale , Wang, Bin , Wang, Ying

American Journal of Physiology-Gastrointestinal and Liver Physiology | February 27, 2024 | Volume: 326 | Issue: 4 | Pages: G473-G481

10.1152/ajpgi.00013.2024 Get It

This study presents a streamlined, cost-effective genotyping workflow for clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) edited mouse models, focusing on trypsinogen genes. It simplifies initial F0 mouse screening using PCR and Sanger sequencing without needing exact sequences. For F1 mice, precise editing is identified through Sanger sequencing and algorithm decoding. The workflow includes a novel PCR strategy for distinguishing homozygous and heterozygous statuses in subsequent generations, effective for small deletions, multiple-gene knockouts, and knockins.